Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Asset disposition
Acq. announced
Director departure
Gene Biotherapeutics, Inc. (CRXM) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/01/2021 SC 13D Form SC 13D - General statement of acquisition of beneficial ownership:
06/01/2020 SC 13D Nostrum Pharmaceuticals, LLC reports a 91.2% stake in GENE BIOTHERAPEUTICS, INC.
01/22/2019 SC 13D Rothenburg Barry reports a 11.2% stake in GENE BIOTHERAPEUTICS INC.
01/08/2015 SC 13D Shanxi Taxus Pharmaceuticals Co., Ltd. reports a 27.5% stake in TAXUS CARDIUM PHARMACEUTICALS GROUP INC.
08/30/2012 SC 13D SABBY MANAGEMENT, LLC reports a 8.6% stake in CARDIUM THERAPEUTICS, INC.
04/01/2004 SC 13D WEINGARTEN ROBERT N reports a 6.5% stake in ARIES VENTURES INC.
01/30/2004 SC 13D MARX DAVID reports a 8.2% stake in David Marx & Lily Marx
04/24/2003 SC 13D Cardium Therapeutics, Inc. reports a 17.4% stake in AQUENTIUM, INC.
06/13/2000 SC 13D MILAN DIVO reports a 6.3% stake in CASMYN CORP.
05/15/2000 SC 13D KYNETON INVESTMENTS LTD reports a 15.2% stake in CASMYN CORP.
06/15/1999 SC 13D ELLIOTT ASSOCIATES, L.P. reports a 10% stake in Casmyn Corp.
07/09/1998 SC 13D ZUCKER MARK S reports a 9.9% stake in Casmyn Corp.
12/22/1997 SC 13D GLOBAL CAPITAL MANAGEMENT INC reports a 9.9% stake in Casmyn Corp.
10/01/1997 SC 13D ROTH MICHAEL reports a 9.9% stake in CASMYN CORP.

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy